Q2 2026 Health In Tech Inc Earnings Call Transcript

Aug 13, 2026 / 09:00 PM GMT

Release Date Price: $1.06 (+3.92%)

Transcript 8-K10-Q

Key Points

Positve

Distribution partner network grew 19.9% year-over-year to 933 brokers, TPAs, and agencies, expanding market reach.
Contracted revenue for H1 2026 reached $32.3 million, with $14 million expected to be recognized in H2 2026, providing strong forward revenue visibility.
Pipeline revenue stood at $66.3 million as of July 31, 2026, with a 15%-40% expected conversion rate, indicating robust future growth potential.
The company secured its first employer group under the three-year rate stabilization program, a key milestone toward capital markets launch.
Hitrix, the new large-group marketplace platform, is on track to launch in H2 2026, opening a significant new growth avenue.
The company is in the process of onboarding an A-rated carrier, which could boost business by 20-30% and unlock access to larger brokerage firms.
The balance sheet remains healthy with $6.5 million in cash and $11.8 million in working capital, supporting continued investment.
The platform's AI-enabled capabilities, such as automated data parsing and real-time quoting, differentiate it from legacy systems.
The company reaffirmed its 2026 revenue guidance of $45-$50 million, backed by strong contracted and pipeline revenue.
The capital-light, partner-driven model allows for scalable growth with linear fixed cost increases.

Negative

Q2 2026 GAAP revenue declined 13.5% year-over-year to $8.1 million, due to timing shifts from new carrier onboarding.
Adjusted EBITDA turned negative at -$1.3 million for the quarter, compared to positive $1.6 million in the prior year period.
Net loss for the quarter was $2.5 million, versus net income of $0.6 million in the same quarter last year.
Operating expenses increased significantly, with sales and marketing expenses up 83% year-over-year to $2.2 million.
Accounts receivable days rose to 55 days in H1 2026, up from 20 days in H1 2025, indicating potential collection delays.
The company's reliance on distribution partners compresses gross margins, which are expected to remain in the 45%-50% range.
The timing shift in policy effective dates creates quarter-to-quarter revenue volatility, making GAAP revenue a less reliable indicator.
The company is still early in its journey, with a small market penetration of less than 0.1% of the addressable market.
The success of the Hitrix launch and the A-rated carrier onboarding are not yet fully reflected in current financials, adding execution risk.
Cash used in operations was $2.9 million in Q2, indicating ongoing cash burn as the company invests in growth.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

HIT.OQ - Health In Tech Inc
Q2 2026 Health In Tech Inc Earnings Call
Aug 13, 2026 / 09:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day, ladies and gentlemen.

Thank you for standing by and welcome to the HealthNTech Second Quarter 2026 Earnings Conference Call.

Currently, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. As a reminder, we are recording today's call.

If you have any objections, you may disconnect at this time.

Now, I would like to turn the conference over to Miss Lori Babcock, Chief of Staff for the company. Miss Babcock, please proceed.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.